VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7471 USD | -2.97% |
|
-14.86% | +4.20% |
| May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechUnknown Attendee (Attendees)There we go, we have sound. Well, a big welcome to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.7471
USD
Average target price
3.725
USD
Spread / Average Target
+398.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.20% | 61.88M | |
| -31.06% | 9.41B | |
| -8.43% | 3.03B | |
| +27.31% | 2.9B | |
| -14.31% | 2.16B | |
| -18.94% | 1.7B | |
| +73.13% | 1.51B | |
| +30.25% | 814M | |
| -1.97% | 760M | |
| -26.73% | 529M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- Transcript : VolitionRx Limited - Analyst/Investor Day